Insulet Stock: Is Wall Street Bullish or Bearish?
Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s trajectory.
Barchart ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Omnipod
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5
Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.
Benzinga ·
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
Insulet's earnings and upgraded guidance recently propelled its stock to S&P 500 leadership, showcasing strong execution in the diabetes care market.
MarketBeat ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
AAP
Barchart
MarketBeat
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Topics
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
